Development and Evaluation of the Self-management Module in Patients W
Development and Evaluation of the Self-management Module in Patients With Multiple Sclerosis
We could not find results for this trial
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Education
What it measured
Main measures
Changes in the self-management scale (Multiple Sclerosis Self Management Revised) scores of patients after the implementation of the self-management module
20 months
Other measures (2)
Changes in the patient engagement (Patient Health Engagement Scale) scores of patients after the implementation of the self-management module
20 months
Changes in the perception of care (Patient Assessment of Chronic Illness Care-PACIC) scores of patients after the implementation of the self-management module
20 months
Who could take part
MS (type not specified) · 18 and over
Show the full criteria
Inclusion criteria
* over 18 years old, * Diagnosed with MS and using medication for at least 45 days, * Approved by the physician to participate in the study, * Giving written consent, * Patients who have been in a stable disease period (attack free period) for at least 30 days
Exclusion criteria
* Has a disability that prevents communication, * Involved in another clinical and/or drug trial, * Patients who are pregnant / planning pregnancy during the study period
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Compared with other chronic disease states, MS patients feel more uncertainty and less control over illness and non-illness aspects of life, and as a result, they have poor self-management abilities. It was thought that providing evidence-based information and using balanced information in terms of risk/benefit in patient education would affect the patient's self management. It is thought that a developed comprehensive self-management module by clinical pharmacist will contribute to the literature and clinical practice, and will positively affect the treatment process of patients. This study is aimed to improve the self-management of MS patients by informing them about the disease, treatment options, and appropriate drug use by the clinical pharmacist, and to analyze the effect of the self-management module in the short and long term by examining the change in patients' self-management, participation in the treatment process and care satisfaction and compliance.
Loading reviews and guidelines…
History
Started
Sept 2020
Main results due
Dec 2021
Finished
Sept 2022